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Abstract
Background: There currently is a need for a non-invasive measure of renal fibrosis. We aim to explore whether
shear wave elastography (SWE)-derived estimates of tissue stiffness may serve as a non-invasive biomarker that can
distinguish normal and abnormal renal parenchymal tissue.
Methods: Participants with CKD (by estimated GFR) and healthy volunteers underwent SWE. Renal elasticity was
estimated as Young’s modulus (YM) in kilopascals (kPa). Univariate Wilcoxon rank-sum tests were used.
Results: Twenty-five participants with CKD (median GFR 38 mL/min; quartile 1, quartile 3 28, 42) and 20 healthy
controls without CKD underwent SWE performed by a single radiologist. CKD was associated with increased median
YM (9.40 [5.55, 22.35] vs. 4.40 [3.68, 5.70] kPa; p = 0.002) and higher median intra-subject inter-measurement estimated
YM’s variability (4.27 [2.89, 9.90] vs. 1.51 [1.21, 2.05] kPa; p < 0.001).
Conclusions: SWE-derived estimates of renal stiffness and intra-subject estimated stiffness variability are higher in
patients with CKD than in healthy controls. Renal fibrosis is a plausible explanation for the observed difference in YM.
Further studies are required to determine the relationship between YM, estimated renal stiffness, and renal fibrosis
severity.
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Background
Chronic kidney disease (CKD) is a major public health
challenge [1]. There are currently 19 million adults in
the US in early stages of CKD and over 640,000 adults
with end stage renal disease (ESRD) [2–4]. Projections
suggest that the number of patients who will require dia-
lysis or transplantation for kidney failure will rise to over
2 million people by 2030 [3, 4].
Advanced CKD is associated with increased morbidity
and mortality [5]. Therefore, it is important to quantify
CKD severity. Currently, CKD is staged based on esti-
mated glomerular filtration rate (eGFR), derived from
serum creatinine values in one of several formulas [2].
Limitations of this measure are well documented, includ-
ing confounding by race, gender, and muscle mass [6].
Intra-renal fibrosis is a final common pathway for all
CKD, with fibrosis degree correlated with disease sever-
ity [7–9]. Non-focal renal biopsy is the only method in
current clinical use for the evaluation of intra-renal
fibrosis. However, non-focal renal biopsy has significant
disadvantages: (1) it is invasive, with risk of major
complications, (2) it is expensive, with costs of greater
than $1000 (US) per procedure, and (3) it is subject to
sampling error, as the biopsy core/s comprise a small
fraction of the renal parenchyma, and highly fibrotic
kidneys often have insufficient glomerular tissue on
biopsy samples to permit accurate histopathologic diag-
nosis [10–12].
Shear wave elastography (SWE) is an emerging ultra-
sound technique that permits the non-invasive measure-
ment of tissue stiffness. SWE uses focused acoustic energy
pulses to produce microscopic tissue displacement, which
induces perpendicular shear waves that are sonographically
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tracked as they progress through tissue. Stiffer tissues have
been shown to have increased shear wave velocities.
Estimates of tissue Young’s modulus (YM), measured in
kilopascals [kPa] can be derived from shear wave velocity,
where higher values correlate with a higher degree of fibro-
sis [13, 14]. This technique has been FDA approved for use
in liver disease and has high sensitivity and specificity to
discriminate between normal and cirrhotic liver [15]. Varia-
tions of SWE have been used to study other organs includ-
ing breast, thyroid, prostate, and renal allografts [16–21].
Prior human and animal studies have shown a correlation
between SWE estimates of renal YM and presence of CKD
or fibrosis [22, 23].
Shear wave elastography has only been used in two
prior studies in native kidneys and has not yet been used
to examine a heterogeneous population of CKD in the
United States [22, 24]. There are limitations to these
prior studies, including lack of non-diseased comparison
group [22]. In this pilot study, we aim to explore
whether SWE-derived estimates of tissue YM may serve
as a non-invasive biomarker that can distinguish normal
and abnormal renal parenchymal tissue.
Methods
Patient population
For this cross sectional pilot study, subjects were recruited
from the outpatient renal clinic panels at an academic
tertiary care center from March 2014 to September 2014.
Inclusion criteria for subjects with CKD included: age
greater than 18 years, eGFR less than 60 mL/min by the
IDMS-traceable, 4-variable MDRD equation [25] or
known diagnosis of CKD, and consent to undergo renal
ultrasound. Exclusion criteria included body mass index
(BMI) greater than 35 kg/m2, pregnancy or nursing status,
or any condition that impeded visualization of the kidney
by ultrasound. Healthy control subjects were screened for
the absence of common medical conditions including
CKD (and/or eGFR < 60 mL/min), hypertension, diabetes,
and cardiovascular disease. Control subjects were re-
cruited at the study site. Inclusion criteria for healthy
subjects included: age greater than 18, BMI less than
35 kg/m2, not pregnant or nursing, and structurally nor-
mal kidneys on traditional renal ultrasound. Participants
were not included or excluded on the basis of race, gender,
or ethnicity. Demographic and medical information was
taken from electronic medical record or by interview. Past
medical history and etiology of CKD were determined by
the participants’ treating providers and were extracted
from medical documentation. Lab values were taken from
the electronic medical record within one month of under-
going SWE, or if values were unobtainable, a study nurse
performed a separate blood draw at the time of SWE.
Study data were collected and managed using REDCap
electronic data capture tools hosted at the Harvard
Clinical and Translational Science Center [26].
Shear wave elastography
Shear wave elastography was performed with a curved
2–5 MHz broadband transducer on a two-port Aixplorer
ultrasound system (Supersonic Imagine, Paris, France).
A single board-certified radiologist (AES) with 13 years
of sonography experience performed all SWE scans for
this study. Participants were scanned in the typical man-
ner renal sonographic images are obtained clinically, in
the position offering the shortest distance to either
kidney, typically the left decubitus or supine positions.
Body position was not recorded. SWE measurements
were obtained in a single region of interest (minimum
diameter 6 mm) an area of renal parenchyma at least
1 cm deep of the capsule in the renal cortex, with spe-
cific avoidance of renal pyramids as the operator was
able. Measurements where obtained where the acoustic
window was optimal, typically in the lower renal pole.
Distance from the skin to the region of interest was re-
corded as kidney depth and listed in Table 1 for cases
and controls. Eight to twelve readings were taken per
subject and a median SWE value was recorded as YM in
kPa (Fig. 1). YM was calculated by Aixplorer software
under the assumption of target tissue at body temperature
using the formula E = ρ x c2, where E is tissue elasti-
city in kPa, ρ is tissue density in kg/m3 and c is shear
wave velocity in m/s [27]. SWE measurements were
obtained at end-expiration. All patients had confirm-
ation of absence of hydronephrosis by traditional ultra-
sound prior to undergoing SWE. In all cases, imaging
began with the right kidney. If the kidney was readily ac-
cessible SWE measurements were obtained. If the right
kidney was deep or the acoustic window was considered
suboptimal by the radiologist, SWE measurements
were obtained from the left kidney. Eighty eight per-
cent of participants underwent SWE on the right
kidney.
Statistical analysis
The characteristics of the study participants by CKD and
control group status were presented using median (quartile
1, quartile 3) or numbers (percentages). The median value
for estimated tissue YM was selected due to the non-
normality of individual measurements. The main outcome
(median estimated tissue YM in kPa) was reported as a
continuous variable and was compared between exposure
variables using Wilcoxon Rank-Sum tests. Intra-subject
variability was examined by comparing difference of indi-
vidual readings from the median YM for each subject.
The diagnostic performance of SWE for distinguishing
normal renal parenchyma from renal parenchyma affected
by CKD was assessed using a univariate logistic regression
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model to construct receiver operating characteristic
(ROC) curves. ROC analyses were performed to determine
a cut point of SWE that would correctly classify the max-
imum number of participants based on sensitivity and spe-
cificity values. Wald asymptotic 95 % confidence limits are
presented for sensitivity and specificity values. Percentile
method 95 % confidence intervals for ROC curves were
generated with 2000 replicate samples using the pROC
package in R version 3.0.2 (Vienna, Austria) [28, 29].
Comparisons of area under the curves were performed by
Table 1 Demographic information
CKD (n = 25) Control (n = 20)
Age (years) 61 (56, 70) 34 (29, 49)
Male Gender 16 (64 %) 5 (25 %)
Ethnicitya
Non-Hispanic 20 (83 %) 18 (90 %)
Hispanic 4 (17 %) 2 (10 %)
Race
White 20 (80 %) 15 (75 %)
Other 5 (20 %) 5 (25 %)
Height (cm) 170.2 (163.0, 177.8) 165.0 (162.8, 169.0)
Weight (kg) 76.0 (71.0, 88.0) 65.8 (61.1, 69.0)
BMI (kg/m2) 26.1 (24.8, 28.4) 23.4 (22.1, 24.0)
Kidney Length (cm) b 10.35 (9.16, 10.95) 10.47 (10.10, 11.07)
Kidney Depth to Region of Interest (cm) 3.60 (1.64, 5.56) 3.15 (2.45, 3.85)
Hematocritc 38.2 (33.6, 40.2) 40.8 (39.6, 41.1)
BUN (mg/dL) d 30 (18, 38) 13 (11, 15)
Creatinine (mg/dL) d 1.74 (1.42, 2.38) 0.90 (0.79, 0.96)
GFR (mL/min) 38 (28, 42) >60
CKD Stage
CKD Stage 1-2 1 (4 %)
CKD Stage 3 17 (68 %)
CKD Stage 4 5 (20 %)
CKD Stage 5 2 (8 %)
Cause of CKD
Diabetes/Hypertension 13 (52 %)
IgA Nephropathy 3 (12 %)
Renovascular Disease 1 (4 %)
Other Known Diagnosis 6 (24 %)
Unknown Diagnosis 2 (8 %)
Other Medical History
Hypertension 24 (96 %)
Hyperlipidemia 18 (72 %)
Diabetes 7 (28 %)
Gout 5 (20 %)
Coronary Artery Disease 5 (20 %)
Congestive Heart Failure 5 (20 %)
Vascular Disease 4 (16 %)
Hypothyroidism 4 (16 %)
Prostatic Hypertrophy 3 (12 %)
All continuous variables are given as medians (quartile 1, quartile 3). CKD stage calculated by MDRD equation. aN = 24 for CKD. bN = 23 for CKD and N = 18 for
controls. cN = 20 for CKD and N = 9 for controls. dN = 9 for controls
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use of a contrast matrix to take differences of the area
under the empirical ROC curves. Pearson correlation coef-
ficients were used to assess the association between
continuous exposure variables. Stratified analysis of the
control and CKD groups were performed to evaluate for
potential significant confounders of SWE values. SAS ver-
sion 9.4 (Cary, NC) was used for all other non-ROC-
related statistical analysis. Two-tailed p values of less than
0.05 were deemed statistically significant.
Ethics statement
Written informed consent was obtained from all study
participants. All responses and patient/provider informa-
tion were de-identified except to members of the research
team. The Partners Human Research Committee for
human subjects approved the study. All clinical investiga-
tion was conducted according to the principles expressed
in the Declaration of Helsinki.
Results
Twenty-five subjects with CKD (“cases”) and 20 healthy
subjects (“controls”) were enrolled. Cases were mostly
male (64 %), white race (80 %), and of non-Hispanic origin
(83 %). For cases, median GFR was 38 (quartile 1, quartiles
3: 28, 42) mL/min; median Cr was 1.74 (1.42, 2.38) mg/dL
(normal range: 0.6-1.50 mg/dL). The majority of cases had
CKD stage III or IV (88 %). A sensitivity analysis excluding
the single patient with stage I/II CKD did not affect pri-
mary outcomes. The most common cause of CKD was
diabetes or hypertension (52 %). Controls were mostly
female (75 %), white race (75 %), and of non-Hispanic
origin (90 %). Median BMI was 26.1 (24.8, 28.4) kg/m2 in
cases and 23.4 (22.1, 24.0) kg/m2 in controls. Median age
was 61 (56, 70) years for cases and 34 (29, 49) years for
controls. Median kidney length was 10.35 (9.16, 10.95) cm
in cases and 10.47 (10.10, 11.07) cm in controls (Table 1).
There was a significantly higher median estimated tissue
YM for cases compared to controls (p = 0.002): median
values were 9.40 (5.55, 22.35) kPa and 4.40 (3.68, 5.70)
kPa, respectively (Fig. 2). Using a cutoff of 5.3 kPa for
median estimated tissue YM, the area under the ROC
curve to distinguish CKD from non-CKD state was 0.78
(95 % CI 0.63-0.92; p = 0.02) with a sensitivity and specifi-
city of 80 % (95 % CI 64 %-96 %) and 75 % (95 % CI 56 %-
94 %), respectively (Fig. 3a). Median intra-subject variabil-
ity of individual estimated YM (distance from the median
YM for each subject) was larger in cases compared to con-
trols (3.88 [2.88, 5.13] vs. 1.41 [1.14, 2.13] kPa; p < 0.001).
Using a cutoff of 2.8 kPa for intra-subject variability, the
area under the ROC curve to distinguish diseased from
healthy renal parenchyma was 0.85 (95 % CI 0.72-0.98;
p = 0.002) with a sensitivity and specificity of 76 %
(95 % CI 55 %-91 %) and 90 % (95 % CI 68 %-99 %),
respectively (Fig. 3b). The estimated areas under the
ROC curve for distinguishing healthy and diseased renal
cortex using median estimated tissue YM or intra-subject
variability were not significantly different (p = 0.15).
Among controls, only race was significantly associated
with estimated tissue YM (p = 0.01). Among cases, esti-
mated tissue YM was associated with female gender
Fig. 1 ROC Curves for Detecting Presence of CKD. Panel (a): Median Young’s Modulus (p = 0.018). Panel (b): Intra-subject Variability of Young’s
Modulus (p = 0.002). P values were derived from logistic regression
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(p = 0.03), kidney depth (p = 0.02), height (p = 0.04), weight
(p = 0.001), and BMI (p = 0.045). There was no correlation
between estimated tissue YM and age or kidney length in
either group (Table 2). For stratified analysis, potential con-
founders were dichotomized into high versus low values at
their respective medians. Among cases, kidney depth was
the only potential confounder that had significantly differ-
ent values: 5.5 kPa [IQR 12.1] with kidney depth greater
than or equal to 3.6 cm versus 12.3 kPa [IQR 18.0] with
kidney depth less than 3.6 cm; p = 0.02. In the control
group, BMI was the only potential confounder that had sig-
nificantly different values: 5.1 kPa [IQR 2.5] with BMI
greater than or equal to 23 kg/m2 versus 3.9 kPa [IQR 1.1]
with BMI less than 23 kg/m2; p = 0.01 (Additional fie 1:
Table S1).
Discussion
Our results suggest estimated tissue YM can be used to
non-invasively distinguish renal tissue affected by CKD
from normal renal tissue, even when kidney size does
not differentiate the two conditions. Of the two prior
human studies examining SWE in native kidneys, one
also reported a correlation between estimated tissue YM
and presence of CKD [24]. The second study, of Chinese
subjects primarily with early stage CKD, was designed to
look for differences between CKD subgroups and did
not include healthy patients as a comparator [22]. Except
for stage V, neither of these studies detected a correl-
ation between estimated tissue YM and CKD stage. This
is unsurprising; the relatively small number of subjects
in these studies suggests they were insufficiently pow-
ered to do so. The potential of SWE to detect diffuse
renal disease is clinically relevant, as conventional B
mode sonography is well known to be insensitive for the
detection of diffuse renal disease, and is presently used
primarily for the exclusion of hydronephrosis [30].
In our study, we make two important assumptions: (1)
we assumed CKD would alter tissue stiffness in a way
Fig. 2 Representative Images of Shear Wave Elastography. Panel (a): right kidney of a subject with CKD. Panel (b): right kidney of a control subject
Fig. 3 Median Estimated Young’s Modulus in CKD versus Controls (Panel a). Median Variability in Intra-subject SWE Readings in CKD and Controls
(Panel b)
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that could be detected by SWE. We considered this
biologically plausible, as renal parenchymal fibrosis and
inflammation are known to occur in CKD, and fibrosis is
known to alter tissue SWE estimates of tissue stiffness in
other organs [16–19]. Our study did not include patients
who underwent contemporaneous kidney biopsy, so we
did not directly measure the relationship between histo-
logic measures of fibrosis and renal stiffness. Since in-
flammation, fibrosis, and renal perfusion abnormalities
all contribute to the clinical CKD syndrome, it is un-
likely that histologic measures of renal fibrosis alone
would have been an appropriate reference standard.
The majority of prior studies examining variations of
SWE technology and renal fibrosis are in renal trans-
plants, and support a positive correlation between SWE
estimates of renal stiffness and pathologic fibrosis or
eGFR, [19–21, 24, 31, 32] though at least two studies
(including one examining native kidneys) did not find a
significant correlation [22, 33]. Potential explanations for
this include SWE technology variation, type II error
owing to small sample sizes, incorrect estimation of
fibrosis by biopsy, which is known to be an imperfect
reference standard, [34] operator variability, or a true
lack of correlation.
A second assumption is that CKD is the cause of tissue
stiffness, rather than other potential confounders. Our
study identified associations between estimated renal
tissue YM and race, gender, kidney depth height, weight,
and BMI, albeit not in both case and control groups. Prior
studies of renal SWE have identified several potential con-
founders, including bladder pressure, [23] renal blood
flow, [23] BMI, [21] kidney depth, [21] surrounding fluid
accumulation, [21] and age [24]. With the exception of
BMI and kidney depth, none of these factors appear across
multiple studies, suggesting these potential confounding
effects may be small or inconsistent. In a large study of
healthy subjects undergoing SWE, there was no difference
in renal cortex readings between men and women [35].
The effect of potential confounders, such as gender and
renal blood flow, remains a potential area of future study
for SWE.
When considering these assumptions, it is relevant to
note that tissue YM, similar to other physical properties
of tissue, such as weight, viscosity, radiodensity, and
acoustic impedance, represents bulk tissue properties,
and is therefore representative of composite endpoints
produced by tissue content, structure, and microenvir-
onment. It is probable that additional situation-specific
Table 2 Evaluation of Potential Influences on SWE in CKD and Control Groups
Factors CKD Control
r P value r P value
Age 0.370 0.07 0.325 0.16
Height −0.423 0.04 −0.235 0.31
Weight −0.556 0.004 0.033 0.90
BMI −0.404 0.045 0.251 0.29
Kidney Length −0.257 0.24 −0.238 0.34
Kidney Depth −0.525 0.007 −0.336 0.15




Young’s modulus Young’s modulus
Race 0.58 0.01
White 10.70 (5.08, 24.85) 4.85 (4.30, 6,85)
Other 7.60 (7.50, 10.50) 3.10 (2.70, 3.90)
Gender 0.04 0.15
Male 6.60 (4.10, 12.33) 3.55 (3.10, 4.20)
Female 22.35 (9.40, 25.80) 4.50 (3.90, 6.20)
Ethnicity 0.87 0.20
Non-Hispanic 10.70 (5.78, 23.13) 4.35 (3.55, 4.90)
Hispanic 5.58 (4.50, 8.05) 6.03 (5.20, 6.85)
Correlation coefficient (r) given for continuous variables. Median Young’s modulus (quartile 1, quartile 3) in kPa given for categorical variables. Abbreviations: BMI
(body mass index), eGFR (estimated glomerular filtration rate), BUN (blood urea nitrogen). aN = 9 for controls
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tissue microenvironment factors, such as inflammation,
may confound SWE estimates of tissue YM. This is
known to be the case in liver disease, where hepatic
inflammation has been shown to increase tissue stiffness
estimates [36]. Despite this, the clinical utility of elasto-
graphy for liver fibrosis staging is now well established,
and SWE is used clinically to differentiate early and
advanced liver fibrosis without biopsy [15]. We antici-
pate SWE may similarly have great utility in diffuse renal
disease as it has the potential both to reduce biopsy use,
and to permit repeated non-invasive direct estimates of
renal parenchymal disease severity. Ultimately, such a
tool could potentially be used to track renal fibrosis
progression and permit therapy individualization in a
manner that is presently not possible.
Our study supports prior evidence that the relation-
ship between SWE estimates of tissue YM and renal
fibrosis severity may not be as robust as that seen in
liver disease. For example, the area under ROC curve for
estimates of YM has been reported to be as high as 0.98
in liver disease [15] versus 0.78 in our study and 0.75 in
Guo et al. [24]. There are several potential reasons for
this, including: (1) greater kidney depth from the skin
surface compared with the liver; (2) the more rounded
renal shape, which may cause refraction of acoustic
displacement pulses with greater variation in renal par-
enchymal shear wave generation; and (3) larger variabil-
ity in the reference standards used for the quantitation
of renal fibrosis than in the relatively simpler liver fibro-
sis staging METAVIR classification.
We showed increased variability in individual SWE
readings in the CKD group. There are two potential rea-
sons for this: (1) SWE may be less precise in stiffer tissue.
A larger standard deviation and range of readings in sub-
groups with advanced fibrosis were observed in prior liver
and kidney studies supporting this notion [15, 19]. (2) Al-
ternatively, there is an intriguing possibility that renal par-
enchymal fibrosis results in true increased heterogeneity
of the tissue YM. If validated, tissue stiffness heterogeneity
could prove a valuable biomarker of fibrosis severity, and
add additional explanatory power to this new technology.
Interestingly, the area under the ROC curve for variability
of measurement was better compared to the estimation of
YM itself, though this was not statistically significant, and
the two predictors together did not create a statistically
significant combined model. Other factors, such as probe
type, tissue depth, and operator technique are still being
explored as explanations of variability in measurements
for this new technology [37–39]. Regardless of the reason
for measurement variation, it is clear that judicious selec-
tion of clinical outcomes and sample size will be necessary
in future studies to supply sufficient power. Studies tar-
geted at fibrosis staging dichotomized at clinically relevant
cut-offs may be more likely to be productive than attempts
to establish a linear relationship between fibrosis stage and
tissue stiffness.
One should interpret these results within the context of
the limitations of our study: (1) as expected for a pilot
study, we were only able to capture a small cross section
of the large and heterogeneous CKD population. Half of
CKD subjects had diabetic or hypertensive kidney disease,
though it is not known if the disease process driving CKD
has an independent effect on YM. (2) We were not able to
control for all factors described as potential confounders
in prior studies. Most notably, we had no measure of renal
blood flow, which was out of the scope of this study. Only
one subject had known renal vascular disease, and exclud-
ing this subject did not affect our conclusions. Kidney
depth may have also influenced shear wave readings,
which could not be controlled for in this pilot study. (3)
Age has been identified as a confounder of YM in prior
studies. The median age of the cases was greater than that
of the controls in our study, which may have biased the
stiffness estimates upward in our case cohort. However,
one prior study, [24] advancing age was moderately in-
versely correlated with renal stiffness. This suggests that
the observed higher renal stiffness in the cases was not
due to relatively higher age in this group. (4) We also used
the known imperfect reference standard of eGFR to esti-
mate CKD severity, and did not have renal biopsy data
available to quantify fibrosis histologically. (5) We did not
measure inter-observation variance given all SWE studies
were performed by a single radiologist. Despite these limi-
tations, we believe our pilot study shows the potential of
SWE to expand the role of ultrasound in CKD beyond the
exclusion of hydronephrosis to the non-invasive and cost-
effective staging of diffuse renal disease.
Conclusions
SWE-derived estimates of renal stiffness and intra-subject
estimated stiffness variability are higher in patients with
CKD than in healthy controls. Renal fibrosis is a plausible
explanation for the observed difference in YM. Shear wave
elastography may be a low-cost way to provide additional
diagnostic information in CKD. Further studies are re-
quired to determine the relationship between YM, esti-
mated renal stiffness, and renal fibrosis severity.
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